MaxCyte, Inc. (NASDAQ:MXCT) CEO Maher Masoud Acquires 29,557 Shares

MaxCyte, Inc. (NASDAQ:MXCTGet Free Report) CEO Maher Masoud purchased 29,557 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was bought at an average price of $4.87 per share, for a total transaction of $143,942.59. Following the acquisition, the chief executive officer now owns 29,557 shares in the company, valued at $143,942.59. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Maher Masoud also recently made the following trade(s):

  • On Monday, June 10th, Maher Masoud bought 70,443 shares of MaxCyte stock. The stock was purchased at an average cost of $4.90 per share, for a total transaction of $345,170.70.

MaxCyte Stock Performance

MXCT stock opened at $4.96 on Tuesday. The firm has a market cap of $517.80 million, a P/E ratio of -14.17 and a beta of 1.45. MaxCyte, Inc. has a 1 year low of $2.45 and a 1 year high of $5.55. The stock has a 50-day simple moving average of $4.28 and a 200-day simple moving average of $4.56.

MaxCyte (NASDAQ:MXCTGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $11.34 million during the quarter, compared to the consensus estimate of $7.75 million. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. On average, equities research analysts predict that MaxCyte, Inc. will post -0.5 EPS for the current year.

Institutional Investors Weigh In On MaxCyte

A number of large investors have recently added to or reduced their stakes in the company. Swedbank AB purchased a new position in MaxCyte in the 1st quarter valued at about $6,704,000. Silvercrest Asset Management Group LLC lifted its stake in shares of MaxCyte by 4.5% in the first quarter. Silvercrest Asset Management Group LLC now owns 699,089 shares of the company’s stock worth $2,929,000 after acquiring an additional 30,209 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in MaxCyte by 20.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock valued at $106,000 after purchasing an additional 4,320 shares during the last quarter. Lazard Asset Management LLC grew its stake in MaxCyte by 27.4% during the 1st quarter. Lazard Asset Management LLC now owns 467,687 shares of the company’s stock valued at $1,958,000 after purchasing an additional 100,555 shares in the last quarter. Finally, Roubaix Capital LLC increased its holdings in MaxCyte by 28.8% during the 1st quarter. Roubaix Capital LLC now owns 497,353 shares of the company’s stock worth $2,084,000 after purchasing an additional 111,152 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on MXCT shares. BTIG Research dropped their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research report on Wednesday, March 13th. Finally, Stephens reissued an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a research report on Tuesday, April 23rd.

View Our Latest Report on MXCT

MaxCyte Company Profile

(Get Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Further Reading

Insider Buying and Selling by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.